arrow
Z

Zahinoor Ismail

University of Calgary
H指数:63
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

White matter hyperintensities moderate neuropsychiatric response to N-acetylcysteine and exercise therapy in vascular mild cognitive impairment

白质高信号调节N-乙酰半胱氨酸和运动疗法对血管性轻度认知障碍患者神经精神反应的影响

2026-10-070
PRE
Tau-PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head-to-head comparison of Flortaucipir and MK6240

帕金森行为障碍在临床前和前驱期阿尔茨海默病中的Tau-PET相关性:Flortaucipir与MK6240的头对头比较

2026-09-290
OAAI
Remote ischemic conditioning in the acute treatment of ischemic and hemorrhagic stroke: A systematic review and meta-analysis of randomized controlled trials

远程缺血后处理在缺血性和出血性卒中急性期治疗中的应用:一项随机对照试验的系统评价和荟萃分析

2026-09-020
OAAI
Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease

常染色体显性遗传阿尔茨海默病前临床期中轻度行为障碍、认知功能与脑病理学之间的关联

2026-08-180
OAAI
Plasma Biomarkers and Clinical Indicators for Identifying Mild Cognitive Impairment in Older Adults With Psychiatric Disorders

血浆生物标志物和临床指标用于识别伴有精神障碍的老年人轻度认知障碍

2026-08-120
PRE
Development and Cross-Sectional Validation of the Quality of Life and Function Five-Domain Scale (QFS-5) in Dementia-Free Community-Dwelling Older Adults

生活质量与功能五领域量表(QFS-5)的开发与横断面验证:在无痴呆社区居住老年人中的研究

2026-04-230
OAAI
Plasma biomarkers in neuropsychiatric syndromes: A narrative review

神经精神综合征中的血浆生物标志物:一篇叙事性综述

2025-11-240
OA
Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation

阿尔茨海默病药物重定位:一项德尔菲共识与利益相关者咨询

2025-11-180
OAAI